Stoke Therapeutics, Inc. announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke?s leadership team, Mr. Hoitt will be responsible for overseeing the Company?s global commercial strategy for STK-001.

Recently announced data support the potential for STK-001 to be the first disease-modifying medicine for the treatment of Dravet syndrome. Prior to joining Stoke, Mr. Hoitt served as Chief Commercial Officer at Provention Bio and led all commercial efforts including pre-launch and launch strategy and execution for Tzield (teplizumab-mzwv), the first drug approved to address the underlying autoimmune cause of type 1 diabetes. Prior to Provention Bio, Mr. Hoitt served as Chief Commercial Officer at Dova Pharmaceuticals and led all commercial efforts including launch strategy and execution for DOPTELET (avatrombopag) for chronic immune thrombocytopenia.

Prior to Dova Pharmaceuticals, Mr. Hoitt was a member of the commercial leadership team at Insmed Incorporated, serving as a Vice President and Head of Sales. Mr. Hoitt also held senior sales, marketing and medical affairs roles at Sarepta Therapeutics, Vertex Pharmaceuticals and Gilead Sciences. Mr. Hoitt has held integral roles in the launch of several innovative medicines, including Arikayce (Insmed), Exondys 51 (Sarepta), and Incivek (Vertex).

Mr. Hoitt holds a B.A. from the College of the Holy Cross.